Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients	Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, basal cell carcinoma, basal cell neoplasm, carcinoma, epithelial neoplasm, neoplasm, skin disorder, skin neoplasm	Recruiting	Phase 2	2026-03-11		NCT06981325

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	34
Regeneron Pharmaceuticals	238
Skin Cancer Center Minden, Department of Dermatology, Johannes-Wesling-Klinikum Minden	1
Universität Duisburg-Essen	21

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
HELIOS Klinikum Erfurt	Erfurt	Germany	8
Helios Klinikum Oberhausen	Oberhausen	Germany	1
Johannes Wesling Klinikum	Minden	Germany	2
Nationales Centrum für Tumorerkrankungen (NCT)	Heidelberg	Germany	1
Universitätsklinikum Erlangen	Erlangen	Germany	20
Universitätsklinikum Leipzig	Leipzig	Germany	22
Universitätsklinikum Tübingen	Tübingen	Germany	11